WilmerHale Advises Thermo Fisher on its Inaugural CHF 1.070 Billion Offering of Bonds

WilmerHale Advises Thermo Fisher on its Inaugural CHF 1.070 Billion Offering of Bonds

Client News

Related Solutions

Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
A deep and diverse practice focused on maximizing tax efficiencies and minimizing tax risks for clients nationally and internationally.

WilmerHale acted as US special counsel to Thermo Fisher Scientific Inc. in connection with its inaugural offer and sale of CHF-denominated bonds, in an offering that was the largest issuance by a foreign issuer of Swiss franc bonds in seven years. The offering consisted of CHF 330,000,000 aggregate principal amount of 1.6525% Bonds due 2028, CHF 415,000,000 aggregate principal amount of 1.8401% Bonds due 2032 and CHF 325,000,000 aggregate principal amount of 2.0375% Bonds due 2036, each to be listed on the SIX Swiss Exchange. The offering priced on February 27, 2024 and closed on March 7, 2024. UBS AG, acting through its business division, UBS Investment Bank, BNP Paribas (Suisse) SA and Deutsche Bank AG London Branch, acting through Deutsche Bank AG Zurich Branch, acted as the joint lead managers for the offering. 

The WilmerHale team advising Thermo Fisher Scientific Inc. on the offering consisted of Molly Fox, Justin Ochs, Andrew Langworthy, Ryan S. Brewer and Rachael Joseph (Capital Markets), with assistance from Julie Hogan-Rodgers (Tax).

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel